Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 4
1992 5
1993 1
1994 1
1995 2
1996 3
1997 2
1998 2
2004 1
2008 4
2009 4
2010 1
2011 5
2012 7
2013 3
2014 7
2015 5
2016 6
2017 5
2018 5
2019 6
2020 5
2021 5
2022 9
2023 5
2024 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

105 results

Results by year

Filters applied: . Clear all
Page 1
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.
Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, Do YR, Feldman T, Gasiorowski R, Jurczak W, Kim TM, Lewis DJ, van der Poel M, Poon ML, Cota Stirner M, Kilavuz N, Chiu C, Chen M, Sacchi M, Elliott B, Ahmadi T, Hutchings M, Lugtenburg PJ. Thieblemont C, et al. Among authors: clausen mr. J Clin Oncol. 2023 Apr 20;41(12):2238-2247. doi: 10.1200/JCO.22.01725. Epub 2022 Dec 22. J Clin Oncol. 2023. PMID: 36548927 Free PMC article. Clinical Trial.
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study.
Hutchings M, Mous R, Clausen MR, Johnson P, Linton KM, Chamuleau MED, Lewis DJ, Sureda Balari A, Cunningham D, Oliveri RS, Elliott B, DeMarco D, Azaryan A, Chiu C, Li T, Chen KM, Ahmadi T, Lugtenburg PJ. Hutchings M, et al. Among authors: clausen mr. Lancet. 2021 Sep 25;398(10306):1157-1169. doi: 10.1016/S0140-6736(21)00889-8. Epub 2021 Sep 8. Lancet. 2021. PMID: 34508654 Clinical Trial.
[Isoniazid-inducedtoxic hepatitis].
Kristensen KL, Nordholm AC, Clausen MR, Katzenstein TL. Kristensen KL, et al. Among authors: clausen mr. Ugeskr Laeger. 2021 Feb 8;183(6):V10200770. Ugeskr Laeger. 2021. PMID: 33570026 Free article. Danish.
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study.
Linton KM, Vitolo U, Jurczak W, Lugtenburg PJ, Gyan E, Sureda A, Christensen JH, Hess B, Tilly H, Cordoba R, Lewis DJ, Okada C, Hutchings M, Clausen MR, Sancho JM, Cochrane T, Leppä S, Chamuleau MED, Gernhardt D, Altıntaş I, Liu Y, Ahmadi T, Dinh MH, Hoehn D, Favaro E, Elliott B, Thieblemont C, Vose JM. Linton KM, et al. Among authors: clausen mr. Lancet Haematol. 2024 Aug;11(8):e593-e605. doi: 10.1016/S2352-3026(24)00166-2. Epub 2024 Jun 15. Lancet Haematol. 2024. PMID: 38889737 Clinical Trial.
Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial.
Thieblemont C, Karimi YH, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, Jurczak W, Do YR, Gasiorowski R, Lewis DJ, Kim TM, van der Poel M, Poon ML, Feldman T, Linton KM, Sureda A, Hutchings M, Dinh MH, Kilavuz N, Soong D, Mark T, Sacchi M, Phillips T, Lugtenburg PJ. Thieblemont C, et al. Among authors: clausen mr. Leukemia. 2024 Dec;38(12):2653-2662. doi: 10.1038/s41375-024-02410-8. Epub 2024 Sep 25. Leukemia. 2024. PMID: 39322711 Free PMC article.
Metabolomics to Explore Impact of Dairy Intake.
Zheng H, Clausen MR, Dalsgaard TK, Bertram HC. Zheng H, et al. Among authors: clausen mr. Nutrients. 2015 Jun 17;7(6):4875-96. doi: 10.3390/nu7064875. Nutrients. 2015. PMID: 26091233 Free PMC article. Review.
Trichinella infection and clinical disease.
Clausen MR, Meyer CN, Krantz T, Moser C, Gomme G, Kayser L, Albrectsen J, Kapel CM, Bygbjerg IC. Clausen MR, et al. QJM. 1996 Aug;89(8):631-6. doi: 10.1093/qjmed/89.8.631. QJM. 1996. PMID: 8935484 Review.
105 results